東京大学 · 医学
石浦弘行教授の研究室は、神経免疫疾患、特に抗NMDA受容体抗体関連脳炎をはじめとする自己免疫性脳症の病態解明と治療戦略の確立を主眼としています。特に、腫瘍を伴わない難治性の脳炎例に対するリツキシマブを用いた積極的免疫療法の有効性を報告しており、臨床的意義の高い治療アプローチの確立を目指しています。また、筋萎縮性側索硬化症（ALS）の集団発症地域・紀の平地域における遺伝的要因の解明にも貢献しています。
Figures are computed from collected data and may differ slightly.
Paraneoplastic encephalitis with antibodies against NR1/NR2 heteromers of the NMDA receptor associates frequently with ovarian teratoma and has recently been established as a distinct clinical entity.1 Most patients are young women who develop a syndrome with prodromal cold-like illness, intractable seizures, psychosis, dyskinesia, and hypoventilation.1,2 However, about 40% of patients do not have a detectable tumor,3 and the treatment of these patients remains unclear. We report a patient with
Our findings indicate that the repeat expansion partly accounts for the high prevalence of ALS in the Kii peninsula.
Rituximab monotherapy was effective in treating the patient; hence, rituximab should be considered as the initial treatment against LYG involving the CNS.
Open papers in the app to read, cite, and organize with AI.
